chufangao/CTO huggingface dataset:
Clinical trial NCT02325414: Prevention of Bone Loss After Acute SCI by Zoledronic Acid
Official title: Prevention of Bone Loss After Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-02-28
Primary completion date: 2020-08-25
Completion date: 2020-08-25
Limitations and caveats: The number of participants in the trial was limited, particularly during the second year in each subgroup. Additionally, the number of women studied was limited but was representative of the general sex distribution observed in people with spinal cord injury.
Clinical trial NCT03424122: INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Official title: A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-07-02
Primary completion date: 2022-06-27
Completion date: 2022-06-27
Plan to share individual participant data: NO
Clinical trial NCT02872272: Amikacin Pharmacokinetic Profile in Plasma and Tissue After an Administration Using Impregnated Dressings in Burned Patient Population
Official title: Amikacin Pharmacokinetic Profile in Plasma and Tissue After an Administration Using Impregnated Dressings in Burned Patient Population
Acronym: AMIKACINE
Sponsor: Assistance Publique Hopitaux De Marseille (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: not enough participants to include
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-06
Primary completion date: 2021-07-09
Completion date: 2021-07-09
Plan to share individual participant data: NO
Clinical trial NCT03428126: Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
Official title: Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 29.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-21
Primary completion date: 2022-05-05
Completion date: 2022-05-05
Clinical trial NCT03946670: A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
Official title: A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
Acronym: STIMULUS-MDS1
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 127.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-04
Primary completion date: 2022-04-26
Completion date: 2024-07-03
Baseline population: Full Analysis Set (FAS): All randomized subjects were included in the FAS (intent-to-treat population) Subject data in the FAS were analyzed according to the treatment and stratum they were assigned to when they were randomized. Efficacy.
Plan to share individual participant data: YES
IPD access criteria: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
Clinical trial NCT05038020: A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)
Official title: A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)
Sponsor: Alkahest, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study terminated due to safety findings in other AKST4290 studies
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-17
Primary completion date: 2021-12-09
Completion date: 2022-04-19
Baseline population: The study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrollment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.
Limitations and caveats: This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on low enrollment number, no data is reported in order to protect and maintain participant privacy/confidentiality.
Plan to share individual participant data: NO
Clinical trial NCT05226299: Cough Desensitization Therapy: Pilot 2
Official title: Cough Desensitization Therapy for Cough Hypersensitivity Syndrome: Pilot 2
Acronym: CDTPilot2
Sponsor: University of Montana (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-01
Primary completion date: 2022-05-30
Completion date: 2022-08-30
Clinical trial NCT03422172: A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men
Official title: An Open Label, Phase 1 Study to Evaluate the PK, Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, Cabotegravir (CAB; GSK1265744) in HIV Uninfected Chinese Men
Sponsor: ViiV Healthcare (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 48.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-04-10
Primary completion date: 2020-04-20
Completion date: 2020-04-20
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT03948646: Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
Official title: A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Sofpironium Bromide Gel, 15% in Subjects With Axillary Hyperhidrosis
Acronym: CARDIGANII
Sponsor: Botanix Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 351.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-04
Primary completion date: 2021-08-13
Completion date: 2021-08-13
Baseline population: Intent-to-treat
Plan to share individual participant data: NO
Clinical trial NCT03738800: A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis
Official title: A Phase 2 Randomized, Multicenter, Double-blind, Vehicle Controlled, 90-Day, Safety, Efficacy & Systemic Exposure Study of Trifarotene (CD5789) Cream HE1 in Adults and Adolescents With Autosomal Recessive Ichthyosis With Lamellar Scale
Sponsor: Mayne Pharma International Pty Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Futility
Enrollment: 65.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-05-01
Primary completion date: 2021-09-03
Completion date: 2021-09-03
Plan to share individual participant data: NO
Clinical trial NCT02124759: Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)
Official title: Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)
Acronym: MicroB1
Sponsor: The University of Texas Health Science Center at San Antonio (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 20.0 (ACTUAL)
Number of arms: 3.0
Start date: 2014-04-02
Primary completion date: 2018-02-23
Completion date: 2020-03-30
Baseline population: Baseline participants were consented and passed screening and completed both high fat and low fat diet while randomized to one of the interventions.
Limitations and caveats: Despite continued recruitment efforts, we had difficulty with subjects fully completing the study due to dissatisfaction with the diets. Evaluable subjects completed both low and high fat diet while randomized to one of the three interventions, and only insulin sensitivity was captured for both the low fat and high fat diets due to the low completion numbers.
Clinical trial NCT04251910: Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia
Official title: A Phase Ib/II, Multicenter, Randomized, Double Blind, Placebo Controlled, Ascending Dose Finding, Efficacy, Pharmacokinetic and Safety Study of BXCL501 In Agitation Associated With Dementia
Acronym: TRANQUILITY
Sponsor: BioXcel Therapeutics Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 100.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-12-27
Primary completion date: 2022-01-24
Completion date: 2022-01-24
Baseline population: The safety population consisted of all patients who received study drug.
Clinical trial NCT02809131: Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.
Official title: Randomized Noninferiority Study of an Antibacterial Envelope Alone Versus Envelope Plus Intraoperative Antibacterial Irrigant and Postoperative Antibiotics to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Patients
Acronym: ENVELOPE
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1010.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-04-01
Primary completion date: 2021-03-31
Completion date: 2021-09-30
Plan to share individual participant data: NO
Clinical trial NCT01675154: Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia
Official title: Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to unavailability of the drug.
Enrollment: 5.0 (ACTUAL)
Number of arms: 4.0
Start date: 2015-11-30
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Baseline population: The baseline characteristics are based on first intervention period assignment. This trial is an adaptive design/flexible design using responsive adaptive randomization. The participants were randomized from the start of the study
Limitations and caveats: Only five patients were enrolled in the study. Two patients completed the study. One subject dropped our after Second Intervention Period. Participation of other two subjects was halted due to unavailability of study medications.~Study Design: Although protocol states This trial is randomized, double-blind cross-over trial, study design was actually not a cross over design, but adaptive/flexible design using a responsive adaptive randomization. Thus Arm/Group were not listed per sequence.
Clinical trial NCT01345136: Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Official title: A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma
Sponsor: Jonsson Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: slow accrual
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-07-01
Primary completion date: 2024-02-06
Completion date: 2024-02-06
Clinical trial NCT01740297: Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
Official title: Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV Melanoma
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 217.0 (ACTUAL)
Number of arms: 3.0
Start date: 2013-02-07
Primary completion date: 2016-08-23
Completion date: 2021-03-09
Baseline population: All enrolled participants
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Clinical trial NCT04115098: Individualizing Anti-Inflammatory Medications for Adults With Axial Spondyloarthritis: A Series of N-of 1 Trials
Official title: Individualizing Anti-Inflammatory Medications for Adults With Axial Spondyloarthritis: A Series of N-of 1 Trials
Sponsor: The University of Texas Health Science Center, Houston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: lack of recruitment
Enrollment: 42.0 (ACTUAL)
Number of arms: 12.0
Start date: 2020-06-25
Primary completion date: 2023-08-11
Completion date: 2023-08-11
Limitations and caveats: Terminated due to lack of recruitment
Plan to share individual participant data: NO
Clinical trial NCT04333290: Study Evaluating the Safety of Myeliviz Myelin-Targeting PET Agent
Official title: Phase 1 Study Evaluating the Safety of [11C]MeDAS Myelin-Targeting PET Agent in Humans
Sponsor: The Cleveland Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Unable to obtain Myeliviz for trial
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2024-07-15
Primary completion date: 2024-07-25
Completion date: 2024-07-25
Plan to share individual participant data: YES
IPD sharing description: data will be available per NIH policies
Clinical trial NCT01721876: Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
Official title: A Phase III Randomised, Double-blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination With Subcutaneous Low-dose Cytarabine vs. Placebo + Low-dose Cytarabine in Patients >=65 Years With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 666.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-01-29
Primary completion date: 2014-08-12
Completion date: 2021-05-28
Baseline population: The randomised set (RS) included all patients who had been randomised at the database snapshot.
Limitations and caveats: The final analysis presented in this report was conducted after 574 Overall Survival events had occurred. The final analysis was exploratory and descriptive.
Plan to share individual participant data: NO
IPD sharing description: Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).~For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Clinical trial NCT03853317: QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
Official title: QUILT-3.063: A Phase 2 Study of Combination Therapy With an IL-15 Superagonist (N-803), Off-the-shelf CD16-targeted Natural Killer Cells (haNK), and Avelumab Without Cytotoxic Chemotherapy in Subjects With Merkel Cell Carcinoma (MCC) That Has Progressed on or After Treatment With a Checkpoint Inhibitor.
Sponsor: ImmunityBio, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Not meeting recruitment goal
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-02-19
Primary completion date: 2021-09-29
Completion date: 2022-09-19
Clinical trial NCT03574753: Lung-MAP S1400K: c-MET Positive
Official title: A Phase II Study of ABBV-399 in Patients With C-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP SUB-STUDY)
Sponsor: SWOG Cancer Research Network (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 28.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-16
Primary completion date: 2019-12-21
Completion date: 2021-07-30
Clinical trial NCT04893915: Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Official title: A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No funding support
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-06-30
Primary completion date: 2024-12-31
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT04607148: A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Official title: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Sponsor: Genentech, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The benefit to risk balance did not support further treatment with galegenimab (FHTR2163).
Enrollment: 144.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-11-16
Primary completion date: 2022-11-14
Completion date: 2022-11-14
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT05022394: Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study
Official title: Phase I/II Study to OVERCOME Resistance to PD-1/PD-L1 Inhibitor Immunotherapy in Advanced Non-Small Cell Lung Cancer - I-OVERCOME Trial
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: No participants Enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-02-18
Primary completion date: 2021-02-18
Completion date: 2021-02-18
Clinical trial NCT04312282: The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors
Official title: An Open-Label Study of the Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors
Sponsor: Odonate Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The Sponsor has discontinued the development of tesetaxel
Enrollment: 93.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-03-06
Primary completion date: 2020-09-30
Completion date: 2021-06-15
Clinical trial NCT01759836: Impact of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer
Official title: A Randomized Double Blind, Placebo-controlled Study Determining the Role of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer
Sponsor: Asan Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 364.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-10-31
Primary completion date: 2021-09-30
Completion date: 2021-09-30
Clinical trial NCT05609656: Electroporation and Immunotherapy in Metastatic Colorectal Cancer
Official title: Calcium Electroporation in Combination With Irreversible Electroporation and Immunotherapy in Patients With Proficient Mismatch Repair System (pMMR) Metastatic Colorectal Cancer - A Prospective, Phase 2 Study
Acronym: ELI
Sponsor: Zealand University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated on the basis on an evaluation of the efficacy and safety of the 4 included and treated patients.
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-01-26
Primary completion date: 2024-04-08
Completion date: 2024-05-02
Plan to share individual participant data: NO
Clinical trial NCT04623684: Efficacy and Safety of Mydriatic Microdrops Compared With Standard Drops for Retinopathy of Prematurity (ROP) Screening: a Pilot Randomized Clinical Trial
Official title: Efficacy and Safety of Mydriatic Microdrops Compared With Standard Drops for Retinopathy of Prematurity (ROP) Screening: a Pilot Randomized Clinical Trial
Sponsor: Aristotle University Of Thessaloniki (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 25.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-24
Primary completion date: 2020-09-22
Completion date: 2020-09-29
Plan to share individual participant data: NO